Nowadays, conventional interventions and treatment strategies based on the single or combined use of chemical hypoglycemic and anti-hyperglycemic drugs, e.g., thiazolidinediones, metformin, sulphonylureas, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) agonists or insulin, and dipeptidyl peptidase-4 (DPP-IV) enzyme inhibitors are the mainstays of diabetes management [8]. This evidence concerns the gene INS and diabetes mellitus.